Age and Ageing Advance Access originally published online on December 13, 2004
Age and Ageing 2005 34(2):125-130; doi:10.1093/ageing/afi003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Age and Ageing Vol. 34 No. 2 © British Geriatrics Society 2005; all rights reserved
Research Paper |
Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low–normal gonadal status
1 University of Adelaide, Department of Medicine, Adelaide, South Australia, Australia
2 Institute of Medical and Veterinary Science, Endocrine Unit, Adelaide, South Australia, Australia
3 St Louis University, Division of Geriatric Medicine & GRECC, VA Medical Centre, St Louis, MO, USA
Address correspondence to: G. Wittert. Fax: (+61) 8 3223 3876. Email: gary.wittert{at}adelaide.edu.au
Abstract
Background: relative androgen deficiency in ageing males is assumed to have adverse health effects. This study assessed the effect of 12 months’ standard dose, oral testosterone, on symptoms attributed to testosterone deficiency in older men with plasma testosterone levels in the low–normal range for young men.
Methods: testosterone undecanoate (TU, 80 mg bid) or placebo was administered for one year to 76 healthy men, 60 years or older, with a free testosterone index (FTI) of 0.3–0.5 and significant symptoms on a questionnaire designed to evaluate androgen deficiency (ADAM). The ADAM was completed at baseline, 6 and 12 months. Hormone and safety data were collected at baseline, 1, 3, 6 and 12 months.
Results: after 12 months, plasma total testosterone was unchanged in both groups and sex hormone binding globulin decreased in the testosterone group (P = 0.01). FTI and calculated bioavailable testosterone (cBT) were greater in the testosterone group as compared with the placebo group (P = 0.021 and 0.025, respectively). There was no significant difference in total symptom score between testosterone and placebo groups after 12 months of oral TU. However, there were trends toward improvements in sadness/grumpiness (P = 0.063), reduced erection strength (P = 0.059) and decreased work performance symptoms (P = 0.077), particularly in men with baseline cBT levels below 3.1 nmol/l.
Conclusions: this study concludes that 80 mg bid oral TU does not improve overall ADAM questionnaire scores in older men with low–normal gonadal status. Oral TU may preserve mood and erectile function, as assessed by this questionnaire, particularly in men with the lowest testosterone levels.
Keywords: testosterone, ageing, men, androgen deficiency, randomised controlled trial, elderly
Received March 31, 2004; accepted in revised form September 23, 2004.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Qaseem, V. Snow, T. D. Denberg, D. E. Casey Jr., M. A. Forciea, D. K. Owens, P. Shekelle, and for the Clinical Efficacy Assessment Subcommittee Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians Ann Intern Med, November 3, 2009; 151(9): 639 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tsertsvadze, H. A. Fink, F. Yazdi, R. MacDonald, A. J. Bella, M. T. Ansari, C. Garritty, K. Soares-Weiser, R. Daniel, M. Sampson, et al. Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis Ann Intern Med, November 3, 2009; 151(9): 650 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tsertsvadze, H. A. Fink, F. Yazdi, R. MacDonald, A. J. Bella, M. T. Ansari, C. Garritty, K. Soares-Weiser, R. Daniel, M. Sampson, et al. Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis Ann Intern Med, October 19, 2009; (2009) 0000605-200911030-00150v1. [Abstract] [Full Text]
|
|
|
|
|
|
A. Qaseem, V. Snow, T. D. Denberg, D. E. Casey Jr., M. A. Forciea, D. K. Owens, P. Shekelle, and for the Clinical Efficacy Assessment Subcommittee Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians Ann Intern Med, October 19, 2009; (2009) 0000605-200911030-00151v1. [Abstract] [Full Text]
|
|
|
|
 |
|
 Minerva BMJ, April 9, 2005; 330(7495): 854 - 854. [Full Text] [PDF]
|
|